# Tentarix Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tentarix-biotherapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.tentarix.com
- Total disclosed funding: $85M
- Latest round: Series B (Aug 28, 2023)
- Investors on record: 4

## About

Tentarix Biotherapeutics, Inc. is dedicated to advancing multifunctional biologics aimed at oncology and immunology, showcasing innovative therapeutic strategies and precise targeting capabilities through its patented Tentacles platform.Founded in 2020, Tentarix Biotherapeutics, Inc. operates from San Diego, US, focusing on the development of biologic candidates for cancer and immune-related diseases. The company was established by founders Margaret Karow, Michael Gallo, and Paul K. Donald Santel and Paul Grayson currently serve as CEO. In August 2023, Tentarix secured USD 35.00 mn in Series B funding, led by Amplitude with participation from Gilead Sciences, Inc. and others, raising the total amount raised to USD 35.00 mn from two deals.Tentarix Biotherapeutics specializes in developing multifunctional biologics, particularly conditionally-active, multi-specific biologics for oncology and immunology applications. Their flagship product line, "Tentacles," focuses on analyzing cell surface proteomes for precise targeting, enhancing treatment efficacy while minimizing side effects. These biologics cater to healthcare providers, research institutions, and pharmaceutical companies in cancer and immune disease treatment markets across North America, Europe, and select regions in Asia.Tentarix Biotherapeutics generates revenue through partnerships with established pharmaceutical companies, such as AbbVie, focusing on B2B transactions that involve the co-development and distribution of proprietary biologic candidates. Revenue streams include milestone payments and royalties linked to successful development phases, along with potential sales of Tentacles products in clinical and commercial contexts. Pricing strategies for products and services are determined collaboratively with partners to align with market needs.Following the recent Series B funding of USD 35.00 mn raised in August 2023, Tentarix Biotherapeutics plans to utilize these resources to further develop its Tentacles platform. The company aims to enhance its product offerings in oncology and immunology while targeting new geographic regions for expansion. Specific markets in North America, Europe, and parts of Asia are prioritized for growth as Tentarix continues to innovate and address significant unmet therapeutic needs.

## Funding rounds

- Series B, Aug 28, 2023, $35M — Versant Ventures, Gilead Sciences, Inc., Samsara BioCapital, Amplitude
- Series A, Oct 14, 2021, $50M — Versant Ventures, Samsara BioCapital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Gilead Sciences, Inc. — Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series B